Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPlanas Vilaseca, Alejandra
dc.contributor.authorSimó Servat, Olga
dc.contributor.authorHernández Pascual, Cristina
dc.contributor.authorOrtiz Zuñiga, Angel Michael
dc.contributor.authorMarsal Mora, Josep Ramon
dc.contributor.authorHerance Camacho, José Raul
dc.contributor.authorFerreira González, Ignacio
dc.contributor.authorSimó Canonge, Rafael
dc.date.accessioned2022-06-15T12:53:23Z
dc.date.available2022-06-15T12:53:23Z
dc.date.issued2021-12
dc.identifier.citationPlanas A, Simó-Servat O, Hernández C, Ortiz-Zúñiga Á, Marsal JR, Herance JR, et al. Diabetic Retinopathy and Skin Tissue Advanced Glycation End Products Are Biomarkers of Cardiovascular Events in Type 2 Diabetic Patients. J Pers Med. 2021 Dec;11(12):1344.
dc.identifier.issn2075-4426
dc.identifier.urihttp://hdl.handle.net/11351/7689
dc.descriptionCardiovascular disease biomarkers; Diabetic complications; Type 2 diabetes
dc.description.abstractRisk of cardiovascular events is not homogeneous in subjects with type 2 diabetes; therefore, its early identification remains a challenge to be met. The aim of this study is to evaluate whether the presence of diabetic retinopathy and accumulation of advanced glycation end-products in subcutaneous tissue can help identify patients at high risk of cardiovascular events. For this purpose, we conducted a prospective study (mean follow-up: 4.35 years) comprising 200 subjects with type 2 diabetes with no history of clinical cardiovascular disease and 60 non-diabetic controls matched by age and sex. The primary outcome was defined as the composite of myocardial infarction, coronary revascularization, stroke, lower limb amputation or cardiovascular death. The Cox proportional hazard multiple regression analysis was used to determine the independent predictors of cardiovascular events. The patients with type 2 diabetes had significantly more cardiovascular events than the non-diabetic subjects. Apart from the classic factors such as age, sex and coronary artery calcium score, we observed that the diabetic retinopathy and advanced glycation end-products in subcutaneous tissue were independent predictors of cardiovascular events. We conclude that the diabetic retinopathy and advanced glycation end-products in subcutaneous tissue could be useful biomarkers for selecting type 2 diabetic patients in whom the screening for cardiovascular disease should be prioritized, thereby creating more personalized and cost-effective medicine.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesJournal of Personalized Medicine;11(12)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectRetinopatia diabètica
dc.subjectGlicosilació
dc.subjectCor - Malalties - Factors de risc
dc.subject.meshDiabetic Retinopathy
dc.subject.meshGlycation End Products, Advanced
dc.subject.meshCardiovascular Diseases
dc.subject.mesh/diagnosis
dc.titleDiabetic Retinopathy and Skin Tissue Advanced Glycation End Products Are Biomarkers of Cardiovascular Events in Type 2 Diabetic Patients
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/jpm11121344
dc.subject.decsretinopatía diabética
dc.subject.decsproductos finales de la glicación avanzada
dc.subject.decsenfermedades cardiovasculares
dc.subject.decs/diagnóstico
dc.relation.publishversionhttps://doi.org/10.3390/jpm11121344
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Planas A, Simó-Servat O, Hernández C, Ortiz-Zúñiga Á, Simó R] Unitat de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spanish Institute of Health (ISCIII), 28029 Madrid, Spain. [Marsal JR, Ferreira-González I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER en Epidemiología y Salud Pública (CIBERESP), Spanish Institute of Health (ISCIII), 28029 Madrid, Spain. [Hernández C] Grup de Recerca en Imatge Molecular Mèdica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBBIM-Nanomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERBBN, Spanish Institute of Health (ISCIII), 28029 Madrid, Spain
dc.identifier.pmid34945815
dc.identifier.wos000738266800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record